Skip to content

Study · Systematic review · 2022

3 results

The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.

Fan F, Fan F, Liu H, Shi X, Ai Y, Liu Q, Cheng Y

Journal of Alzheimer's disease : JAD1 Jan 2022Cited by 40 (Europe PMC)

PMID34924395 (opens in a new tab)DOI10.3233/jad-215423 (opens in a new tab)PepBankPUB-34924395
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In AD patients, the umbrella review found that Cerebrolysin appeared beneficial for cognitive performance.

    In plain wordsIn AD patients, the review found that Cerebrolysin appeared to improve thinking performance.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive performance
    Study

    n: not reported in source

    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear to be beneficial for cognitive, global performances, and activities of daily living in patients with AD.
    1 context sentence
    Summary · context
    We conducted a search for meta-analyses and systematic reviews on the Embase, PubMed, The Cochrane Library, and Web of Science to address this knowledge gap.
  2. 02HumanSystematic reviewEfficacy outcome

    In AD patients, the umbrella review found that Cerebrolysin appeared beneficial for global performance.

    In plain wordsIn AD patients, the review found that Cerebrolysin appeared to improve overall performance.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseGlobal performance
    Study

    n: not reported in source

    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear to be beneficial for cognitive, global performances, and activities of daily living in patients with AD.
    1 context sentence
    Summary · context
    We conducted a search for meta-analyses and systematic reviews on the Embase, PubMed, The Cochrane Library, and Web of Science to address this knowledge gap.
  3. 03HumanSystematic reviewEfficacy outcome

    In AD patients, the umbrella review found that Cerebrolysin appeared beneficial for activities of daily living.

    In plain wordsIn AD patients, the review found that Cerebrolysin appeared to improve daily activities.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseActivities of daily living
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results showed that AChE inhibitors (donepezil, galantamine, rivastigmine, Huperzine A), Ginkgo biloba, and cerebrolysin appear to be beneficial for cognitive, global performances, and activities of daily living in patients with AD.
    1 context sentence
    Summary · context
    We conducted a search for meta-analyses and systematic reviews on the Embase, PubMed, The Cochrane Library, and Web of Science to address this knowledge gap.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.